6/9/2023 0 Comments Majestic trialsThese forward-looking statements include, among other things, statements regarding clinical trials and impact of data, product performance and impact, markets for our products, and competitive offerings. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us atthe time and arenot intended to be guarantees of future events or performance. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E ofthe Securities Exchange Act of 1934. For more information, visit and connect on Twitter and Facebook.Ĭautionary Statement Regarding Forward-Looking Statements As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. It is estimated that 12-14 percent of the general population is affected by PAD 2.īoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As the disease progresses, plaque accumulation may significantly reduce blood flow through the arteries, resulting in pain and increasing disability, with severe cases often leading to amputation of the affected limb. Peripheral artery disease is a circulatory disorder that results from a build-up of plaque in one or more of the arteries, most often in the legs. The Ranger™ Paclitaxel-Coated PTA Balloon Catheter has CE Mark approval and is not available for use or sale in the U.S. The Eluvia Stent System is pending CE Mark and is not available for use or sale in the U.S. “Together with our Ranger™ drug-coated balloon, we are providing important new tools for physicians to address a serious condition and make a meaningful difference in the lives of their patients.” “The Eluvia Stent System strengthens our leadership in peripheral technologies and further demonstrates our commitment to developing innovative and effective therapies for the treatment of peripheral artery disease,” said Jeff Mirviss, president, Peripheral Interventions, Boston Scientific. A triaxial delivery system is designed for added support and placement accuracy. The innovative stent architecture, designed specifically for the SFA, features a closed-cell design at each end of the stent for more predictable deployment, and an open-cell design along the stent body for improved flexibility, strength and fracture resistance. The Eluvia Stent System is built on the Innova™ Stent System platform consisting of a self-expanding nitinol stent with a paclitaxel-eluting biostable polymer matrix loaded on an advanced, low-profile delivery system. The Eluvia Stent System is the first stent purpose-built for the superficial femoral artery (SFA) that utilizes a polymer and paclitaxel combination designed to facilitate a sustained drug release to reduce restenosis.
0 Comments
Leave a Reply. |